Our Technology

Developing proprietary oncolytic immunotherapy combinations

ImmVirX is developing novel oncolytic immunotherapy combinations that harness the power of certain viruses to preferentially infect and kill cancer cells and induce systemic anti-tumour immune responses. Our viral candidates are intended to increase the effectiveness of current immunotherapies in fighting cancers of high unmet need.
Therapeutic Strategy

Powerful New Oncolytic Viruses

Harnessing the immune system to fight cancer has become established as one of the pillars of cancer treatment over the past decade, with the introduction of multiple new immunotherapies designed to activate innate or adaptive immune responses. However, many of these approaches have not proved useful in solid tumors, at least in part due to the immunosuppressive status in the tumour microenvironment (TME).

The goal of oncolytic virotherapy is to overcome immune inhibitions in the TME and thus improve the activity of immune checkpoint inhibitors (ICIs) against cancers of high unmet need. ICIs are cornerstone immuno-oncology treatments, with several forecast to be among the biggest selling drugs in the next decade.

ImmVirX is developing proprietary oncolytic RNA viruses which have been bio-selected to have the greatest potency and ability to replicate in and subsequently kill target tumour cells rather than healthy cells, leading to the potential generation of specific and adaptive immune responses against cancer. Our goal is to use these viruses to enhance the rate, depth, and durability of response to immune checkpoint therapy.

Specifically, our oncolytic viruses are being developed to:

  • Highly inflame “cold” tumour types with current low responsiveness to ICI therapy
  • Infiltrate tumour with immune cells at a high rate
  • Trigger both innate and adaptive immune responses
  • Enable synergy with ICI and CAR-T therapies by activating immune stimulating genes, including through the RIG-I pathway
  • Be well tolerated in patients
Clinical Development

Our Pathway

ImmVirX has defined a clear pathway for our proprietary viruses from pre-clinical evaluation to the first clinical trials in 2021.

We are targeting cancers with high unmet need, including colorectal, gastric, pancreatic and ovarian cancer.
Explore Sections
In the News

View our recent news stories

Discover the latest news articles featuring ImmVirX, including research innovations, stories about our people and reports from the latest events.

View All Stories

Join Our Mailing List

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Our mission is to improve outcomes for patients with cancers in which immunotherapy treatments have limited effect